Six Tips For Buying Diamonds From Expert Diamond Dealers
The Mediterranean Blue Diamond, sold for $21.2 million at Sotheby's Geneva May 2025.
The Mediterranean Blue diamond became the highest-value diamond to sell at auction this year, when it went for $21.2 million at Sotheby's Geneva last week. Unearthed at the Cullinan mines in South Africa in 2024, the 10-carat Fancy Vivid Blue diamond eventually sold to an American collector after a three-minute bidding battle. If you're thinking of adding to your own collection — albeit at a different price point — the diamond dealers of GemGenève gem and jewelry show have the insider knowledge you need.
A Fancy Greenish-Yellow diamond was also on sale at Sotheby's Geneva earlier this month.
Examine potential diamond purchases in good lighting with a loupe, noting shape, brilliance, color and any chips or damage. 'Before looking at any certification, you need to trust your eye. Do you like it? What does your gut feeling say?' asks Constantin Torroni, of Nicolas Torroni, an art, gemstones and jewelry dealer based in Geneva, Switzerland. A diamond's natural colors will show up well in daylight, whereas artificial light will affect how different highlights may appear.
Reputable diamond dealers will be able to provide a diamond analysis report from an independent lab — look for expert organizations like the GIA, Gübelin, the BGI and the Swiss Gemmological Institute SSEF. 'A diamond grading report offers reassurance by guaranteeing the natural nature of a gemstone and providing details of its properties,' says Claudia Hamann, of Claudia Hamann Edelstein Double Rose gemstones.
A old-cut diamond dated back to the Renaissance, approx. 3 carats, thought to have been cut by the ... More famous Venetian lapidiarist Vincenzo Peruzzi.
White diamonds graded D, E or F may command the highest prices as 'investment diamonds', but according to Torroni, 'charming gemstones' with colored highlights, inclusions, and even minor damage might offer better value for money. In addition to having more perceived charm and character, their value will also hold up better in times of crisis, as they are less vulnerable to speculation, says Torroni.
Original and new cuts mean fresh inspiration for jewelry designers and interesting acquisitions for collectors. Look beyond the traditional princess-cut stones, to geometric cuts (Asscher, emerald); fancy cuts (pear, marquise), or rarer cuts like Ashoka, a modified cushion cut. Hamann, a member of the International Colored Gemstones Association (ICGA), created the asymmetrical Double Rose cut a few years ago.
Rose quartz, Malayan garnets, brilliant and Double Rose cut pink sapphires, by Claudia Hama ... More Edelstein.
FEATURED | Frase ByForbes™
Unscramble The Anagram To Reveal The Phrase
Pinpoint By Linkedin
Guess The Category
Queens By Linkedin
Crown Each Region
Crossclimb By Linkedin
Unlock A Trivia Ladder
Antique gems and diamonds, also known as 'old cuts', were hand-cut without modern machinery anything from one to four hundred years ago. With softer shapes and unique luminosity, these stones come into their own in gentle candlelight. 'Hand-cut diamonds are true works of artistry, redolent of history and expertise in a way that makes them truly unique,' say Alain Weinberger, Dean Köning and Julien Lorincz of Fima Diamonds. Experts can date these diamonds based on the quality of faceting, which tells us about the tools used.
Precision-cut modern stones will all look very similar, while many collectors believe that old cuts possess their own special character because they were made by a craftsman using hand-tools. 'This artisanal dimension provides a blend of excellence and imperfection and is exceptional in every sense of the word,' say Weinberger, Köning and Lorincz, comparing the stones to standardized modern cuts. Diamonds from the Golconda mines are highly prized, as are Mazarin and Peruzzi antique cuts, both popular in the 17th century.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
US prepares action targeting allies' chip plants in China, WSJ reports
(Reuters) -A U.S. official has informed leading global semiconductor companies of plans to cancel waivers allowing them to use American technology in China, the Wall Street Journal reported on Friday, citing people familiar with the matter. Jeffrey Kessler, under secretary of commerce for industry and security at the Commerce Department, told Samsung Electronics, SK Hynix and Taiwan Semiconductor Manufacturing this week that he wanted to cancel those waivers, WSJ reported. Shares of U.S. chip equipment makers that supply chipmaking plants in China fell on the news. KLA Corp dropped 3.8%, Lam Research fell 4.7% and Applied Materials sank 3.8%. A Commerce Department spokesperson said in a statement, 'Chipmakers will still be able to operate in China. The new enforcement mechanisms on chips mirror licensing requirements that apply to other semiconductor companies that export to China and ensure the United States has an equal and reciprocal process.' The move would make it harder for foreign chipmakers to operate in China where they produce semiconductors used in a wide range of industries.
Yahoo
22 minutes ago
- Yahoo
Stock Market Today: Techs sag on report U.S. will limit chip exports
Stock Market Today: Techs sag on report U.S. will limit chip exports originally appeared on TheStreet. Updated 11:45 a.m. EDT Stocks have lost their early gains on reports the Trump administration is planning to revoke waivers that allow chip companies to use American chipmaking technology in China. The Philadelphia Semiconductor Index and the VanEck Semiconductor ETF () were both off 1.3%. The catalyst was a Wall Street Journal report that a top Commerce Department official has told chip manufacturers like Taiwan Semiconductor () he wants to revoke waivers that gave them blanket permission to use American technology at their plants in China. Instead, the Commerce Department would require export licenses on each instance of using U.S. technology in China, The Journal reported. The idea, if enacted, would affect U.S. trade negotiations with China and could boost costs for the chipmakers. As a result, the Standard & Poor's 500 Index was flat at 5,980. It had been as high as 6,018 early in the day. The Nasdaq-100 Index, which includes key chipmakers, was down 43 points to 21,677. It had been as high as 21,902. Taiwan Semi was off 1.7% to $210. The Dow Jones Industrial Average was still up 159 points to 42,331. Updated 10:20 a.m. EDT Stocks jumped at the open, then faded slightly as investors seemed relieved that the U.S. was holding off on deciding whether to join Israel's war against Iran. At 10 a.m. EDT the Standard& Poor's 500 Index had climbed 16 points to 5,997. The Dow Jones Industrial Average had jumped 167 points to 42,339. 💸💰Don't miss the move: Subscribe to TheStreet's free daily newsletter 💰💸 The Nasdaq Composite Index had risen 32 points to 19578, and the Nasdaq-100 index was up 53 points to 21,772. President Trump said Thursday he expected to decide the question within two weeks. Trump frequently delays decisions like these. His Republican Party has split between isolationists, who form the core of the MAGA side, and hawks, who favor attacking Iran to disable the country's nuclear ambitions. Crude oil and gold prices were lower as war fever ebbed. Crude was off 52 cents to $74.60. Gold was down $28 to $3,380. Silver, which hit a 52-week high of $37.41 per ounce on Wednesday, had fallen 98 cents to $35.94 but was still up 22.2% for the year. It's not easy being Federal Reserve Chairman Jerome Powell. A day after the Fed held interest rates steady, President Trump was raging about the decision. Bill Pulte, chairman of the Federal Housing Finance Agency, was calling on the Fed chairman to cut rates or resign. Christopher Waller, a Fed governor (and believed to covet the chairman's job), told CNBC Friday he thinks a rate cut could come early as the Fed's July 29-30 meeting Powell's term as chairman doesn't end until May 2026, and Trump has basically guaranteed he won't be offered a third battle has to do with how the Fed is affecting mortgage rates. Currently, a 30-year mortgage will cost about 6.8% to 6.9%. Housing data are generally weak, and building optimism is seriously depressed. While Powell is the de facto leader of the Federal Open Market Committee, the Fed's rate-making body, he is only one of more than a dozen central bank officials who vote on the bank's interest rate moves. Even so, Trump has raged at Powell for more than seven years after the president elevated him to lead the Fed in 2017. Investors seemed relieved early Friday after President Donald Trump said he'd decide within two weeks whether to commit America to join Israel in its war against Iraq. Oil prices were falling with crude oil down 39 cents to $73.11. 💵💰💰💵 Trump's decision seemed to surprise many after he'd called for "unconditional surrender" from Iran over its nuclear aspirations. But Trump ally Steve Bannon, a vocal opponent of going to war, visited the White House on Thursday. Futures trading suggests the Standard& Poor's 500 Index will open 8 points higher. The Dow Jones Industrial Average was looking at an opening increase of about 67 points, and Nasdaq-100 futures were up about 50 points. U.S. markets had been closed Thursday for the Juneteenth holiday. Shares of Accenture () were off 2% preopen even as the consulting giant reported better-than-expected earnings and revenue. Barron's cited weak bookings and leadership changes for the decline. Shares of supermarket operator Kroger () were up 1% to $66.25. . Building-materials supplier GMS () shares were up 27% premarket to $101 as a bidding war for the company erupted between Home Depot () and Brad Jacobs' QXO. GMS has a market capitalization of about $3.1 billion. Wall Street believes the bidding is already at $5 billion. The 10-year note yield was up slightly at 4.436%.Stock Market Today: Techs sag on report U.S. will limit chip exports first appeared on TheStreet on Jun 20, 2025 This story was originally reported by TheStreet on Jun 20, 2025, where it first appeared.
CNBC
27 minutes ago
- CNBC
Healthy Returns: What to know about the FDA's plan to speed up some drug reviews
The Food and Drug Administration proposed a dramatic expansion of its power to speed up drug reviews. The agency on Tuesday announced a new national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are supporting "U.S. national interests." Currently, the FDA has a deadline of 10 months after a company files a drug application to make an approval decision. That review period is shortened to six months if a company has been granted a priority review. "The ultimate goal is to bring more cures and meaningful treatments to the American public," FDA Commissioner Marty Makary said in a release. The new voucher program is different from the FDA's existing efforts to speed up review processes. The plan is designed for companies to submit "the lion's share" of a drug application to the agency even before they have final results from a pivotal clinical trial, a process that Makary said would reduce inefficiencies. The FDA may also grant an accelerated approval to products in the new voucher program, which will include "enhanced" communication with companies while their application is under review. The agency said it may extend the review period if the application is particularly complex or if there is insufficient information to support it. In the first year of the program, the FDA plans to give a limited number of vouchers to companies aligned with what it called "national health priorities." That includes addressing a health crisis in the U.S., delivering "more innovative cures" to Americans, addressing unmet public health needs and "increasing domestic drug manufacturing as a national security issue." The criteria come as the Trump administration encourages the pharmaceutical industry to reshore drug manufacturing through executive orders and potential tariffs on medicines imported into the U.S. In a note on Tuesday, Jefferies analyst Michael Yee said the criteria are broad but appear to be positive for the pharmaceutical industry. The program could be more effective than tariffs at encouraging drugmakers to bring their manufacturing to the U.S. But questions remain about the risks of speeding up drug reviews to as little as 30 days – the fastest the FDA has ever done. Another potential concern is whether the vouchers will be offered to political allies of the Trump administration, which could include companies that the FDA staff would normally scrutinize. We'll be looking out for more information on the new plan, so stay tuned. Feel free to send any tips, suggestions, story ideas and data to Annika at Virtual mental health startup Headspace announced a new direct-to-consumer therapy service this week called Therapy by Headspace. It's new territory for the company, which has spent the last decade selling its product to employers and health plans. The new service is available to more than 90 million Americans through Headspace's 45 in-network partnerships with insurers, including UnitedHealthcare, Cigna and Blue Cross Blue Shield. "Headspace now can be your mental health companion, be there for the everyday, whether you need help with sleep, stress, anxiety or you need access to a therapist," Headspace CEO Tom Pickett told CNBC in New York City on Wednesday. "We've got it all, and we've got it in an insurance-backed way, so that we can hopefully make this really inexpensive for you." Pickett, who took on the chief executive role in August, said the new Therapy by Headspace service is part of his vision to round out the company's consumer offerings. Therapy by Headspace users can access one-on-one video sessions with licensed therapists, and most covered members will pay between $0 and $35 per session. If a user's insurance does not cover the offering, they have the option to pay $149 per session out of pocket. Headspace said it plans to add more in-network partners over time. Users will also get three months of access to the sleep, meditation and stress exercises on the Headspace app, as well as Ebb, an artificial intelligence chatbot that can converse and direct people to the best available content. Over time, Ebb will also help generate personalized care plans for each member, Headspace said. "We have not been fully serving the audience that we have, and so launching therapy to consumers made a lot of sense," Pickett said. Headspace, founded in 2010, has raised a total of more than $350 million from investors like Khosla Ventures, Kaiser Permanente Ventures and Cigna Ventures, according to PitchBook. Pickett said Headspace is "running neutral" and in "a very healthy economic position right now." In the near term, the company isn't looking to raise more capital, and is instead focused on building out its offerings and inking new partnerships. "The ultimate goal is really to become the 'Easy Button' in mental health," Pickett said. Feel free to send any tips, suggestions, story ideas and data to Ashley at
